GAMMA Investing LLC Purchases 221,202 Shares of United Therapeutics Co. (NASDAQ:UTHR)

GAMMA Investing LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29,415.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 221,954 shares of the biotechnology company's stock after purchasing an additional 221,202 shares during the quarter. GAMMA Investing LLC owned about 0.49% of United Therapeutics worth $68,422,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its position in shares of United Therapeutics by 15.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company's stock worth $1,991,000 after buying an additional 769 shares during the period. NorthCrest Asset Manangement LLC grew its position in United Therapeutics by 1.5% in the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,598 shares of the biotechnology company's stock valued at $1,975,000 after purchasing an additional 84 shares during the period. Lansforsakringar Fondforvaltning AB publ acquired a new stake in United Therapeutics in the 4th quarter valued at $4,778,000. Siemens Fonds Invest GmbH acquired a new stake in United Therapeutics in the 4th quarter valued at $162,000. Finally, Park Square Financial Group LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $217,000. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other news, Director Raymond Dwek sold 4,000 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $497,962.50. This represents a 69.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,500 shares of company stock valued at $16,923,950. 10.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday. They set an "overweight" rating and a $405.00 price objective on the stock. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Morgan Stanley lifted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $393.00.

United Therapeutics Price Performance

NASDAQ UTHR traded down $0.23 on Wednesday, reaching $323.97. 390,841 shares of the company's stock traded hands, compared to its average volume of 440,270. United Therapeutics Co. has a 12 month low of $266.98 and a 12 month high of $417.82. The stock has a 50-day simple moving average of $300.11 and a 200 day simple moving average of $334.17. The stock has a market cap of $14.61 billion, a PE ratio of 14.23, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same period last year, the business earned $6.17 earnings per share. The business's quarterly revenue was up 17.2% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.